Abstract 14333: YJP14, the Standardized Extract of Lindera Obtusiloba, Ameliorate Endothelial Dysfunction and Suppress Atherosclerotic Plaque Progression by Suppressing NADPH Oxidase-Induced Reactive Oxygen Species Generation in Murine Atherosclerosis Model
Background: YJP14, the standardized extract of Lindera obtusiloba which is traditionally used for cardiovascular diseases in Korea, is recently entered into IND investigation for prevention of endothelial dysfunction. The aim of this study was to determine whether YJP14 prevents the development of atherosclerosis including endothelial dysfunction and formation of atherosclerotic plaque in ApoE-/- mice model.
Methods: The effect of YJP14 on different parameters was compared to losartan (LSRT) that was reported to improve endothelial dysfunction. Three groups of 14 male ApoE-/- mice (Western Diet) and one group of 14 male C57BL/6 (negative control, normal chow) were studied. YJP14 (100mg/Kg/day), LSRT (30mg/Kg/day) and vehicle (Veh, 0.5 % CMC) was administrated by gavage for 20 weeks, from 8 to 28 weeks.
Results: YJP14 slightly, but significantly, decreased the level of LDL, not HDL and TG in ApoE-/- mice. In addition, YJP14 and LSRT prevented endothelial dysfunction (Figure 1), which were, at least in part, associated with reduced vascular expression of NADPH oxidase subunit (p47, p22) and formation of ROS assessed by IHC and DHE staining. Related to vascular remodeling, atherosclerotic plaque lesion area was reduced by YJP14 (0.32 vs. 0.53 mm2 ofcontrol group, p<0.005), not by LSRT. Especially, YJP14 showed strongly plaque inflammation-modulating effects measured by fluorescence reflecting imaging targeted inflammatory endothelial cells (Figure 2) in aorta root.
Conclusion: Taken together, the present findings indicate that YJP14 effectively prevent atherosclerosis plaque progression and is a promising candidate as vasopretective agent.
- © 2012 by American Heart Association, Inc.